Literature DB >> 33415123

Nutritional Interventions in Cancer Cachexia: Evidence and Perspectives From Experimental Models.

Wouter R P H van de Worp1, Annemie M W J Schols1, Jan Theys2, Ardy van Helvoort1,3, Ramon C J Langen1.   

Abstract

Cancer cachexia is a complex metabolic syndrome characterized by involuntary skeletal muscle loss and is associated with poor clinical outcome, decreased survival and negatively influences cancer therapy. No curative treatments are available for cancer cachexia, but nutritional intervention is recommended as a cornerstone of multimodal therapy. Optimal nutritional care is pivotal in the treatment of cancer cachexia, and the effects of nutrients may extend beyond provision of adequate energy uptake, targeting different mechanisms or metabolic pathways that are affected or deregulated by cachexia. The evidence to support this notion derived from nutritional intervention studies in experimental models of cancer cachexia is systematically discussed in this review. Moreover, experimental variables and readout parameters to determine skeletal muscle wasting and cachexia are methodologically evaluated to allow critical comparison of similar studies. Single- and multinutrient intervention studies including qualitative modulation of dietary protein, dietary fat, and supplementation with specific nutrients, such as carnitine and creatine, were reviewed for their efficacy to counteract muscle mass loss and its underlying mechanisms in experimental cancer cachexia. Numerous studies showed favorable effects on impaired protein turnover and related metabolic abnormalities of nutritional supplementation in parallel with a beneficial impact on cancer-induced muscle wasting. The combination of high quality nutrients in a multitargeted, multinutrient approach appears specifically promising, preferentially as a multimodal intervention, although more studies investigating the optimal quantity and combination of nutrients are needed. During the review process, a wide variation in timing, duration, dosing, and route of supplementation, as well as a wide variation in animal models were observed. Better standardization in dietary design, and the development of experimental models that better recapitulate the etiology of human cachexia, will further facilitate successful translation of experimentally-based multinutrient, multimodal interventions into clinical practice.
Copyright © 2020 van de Worp, Schols, Theys, van Helvoort and Langen.

Entities:  

Keywords:  cachexia; cancer; multimodal; multinutrient; multitarget; nutrition; undernutrition

Year:  2020        PMID: 33415123      PMCID: PMC7783418          DOI: 10.3389/fnut.2020.601329

Source DB:  PubMed          Journal:  Front Nutr        ISSN: 2296-861X


  159 in total

1.  Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.

Authors:  Daniel J Ham; Kate T Murphy; Annabel Chee; Gordon S Lynch; René Koopman
Journal:  Clin Nutr       Date:  2013-06-26       Impact factor: 7.324

2.  Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss.

Authors:  Helen J Smith; Pradip Mukerji; Michael J Tisdale
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

3.  A model for malignancy-associated humoral hypercalcemia.

Authors:  E C Abramson; L J Kukla; D H Shevrin; T E Lad; W P McGuire; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

4.  Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children.

Authors:  Peter O Kwiterovich; Eileen P G Vining; Paula Pyzik; Richard Skolasky; John M Freeman
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

5.  Morin suppresses cachexia-induced muscle wasting by binding to ribosomal protein S10 in carcinoma cells.

Authors:  Tomohiro Yoshimura; Kanae Saitoh; Luchuanyang Sun; Yao Wang; Shigeto Taniyama; Kenichi Yamaguchi; Takayuki Uchida; Tsutomu Ohkubo; Atsushi Higashitani; Takeshi Nikawa; Katsuyasu Tachibana; Katsuya Hirasaka
Journal:  Biochem Biophys Res Commun       Date:  2018-10-31       Impact factor: 3.575

Review 6.  Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.

Authors:  Barbara Delage; Dean A Fennell; Linda Nicholson; Iain McNeish; Nicholas R Lemoine; Tim Crook; Peter W Szlosarek
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

7.  Establishment and characterization of a novel murine model of pancreatic cancer cachexia.

Authors:  Katherine A Michaelis; Xinxia Zhu; Kevin G Burfeind; Stephanie M Krasnow; Peter R Levasseur; Terry K Morgan; Daniel L Marks
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-07-20       Impact factor: 12.910

Review 8.  The role of triglyceride lipases in cancer associated cachexia.

Authors:  Suman K Das; Gerald Hoefler
Journal:  Trends Mol Med       Date:  2013-03-14       Impact factor: 11.951

9.  Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice.

Authors:  H J Smith; N A Greenberg; M J Tisdale
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

10.  Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation.

Authors:  S M Wyke; S T Russell; M J Tisdale
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

View more
  12 in total

1.  Primary Tumor Fluorine-18 Fluorodeoxydglucose (18F-FDG) Is Associated With Cancer-Associated Weight Loss in Non-Small Cell Lung Cancer (NSCLC) and Portends Worse Survival.

Authors:  Santiago Olaechea; Bhavani S Gannavarapu; Christian Alvarez; Anne Gilmore; Brandon Sarver; Donglu Xie; Rodney Infante; Puneeth Iyengar
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

2.  Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis.

Authors:  Sabine Kleissl-Muir; Bodil Rasmussen; Alice Owen; Caryn Zinn; Andrea Driscoll
Journal:  Front Nutr       Date:  2022-04-20

Review 3.  The Role of Tumor Microenvironment Cells in Colorectal Cancer (CRC) Cachexia.

Authors:  Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

4.  Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib.

Authors:  Hui Zheng; Qin Pan; Wenchao Zhu; Hongsen Li; Zhongfeng Niu; Yong Fang; Da Li; Haizhou Lou; Hong Hu; Jiawei Shou; Hongming Pan
Journal:  Front Oncol       Date:  2021-03-08       Impact factor: 6.244

Review 5.  Carotenoids in Palliative Care-Is There Any Benefit from Carotenoid Supplementation in the Adjuvant Treatment of Cancer-Related Symptoms?

Authors:  Anna Zasowska-Nowak; Piotr Jan Nowak; Aleksandra Cialkowska-Rysz
Journal:  Nutrients       Date:  2022-08-03       Impact factor: 6.706

Review 6.  Targeting cancer cachexia: Molecular mechanisms and clinical study.

Authors:  Yong-Fei Wang; Zi-Yi An; Dong-Hai Lin; Wei-Lin Jin
Journal:  MedComm (2020)       Date:  2022-09-10

Review 7.  Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy.

Authors:  Bo Li; Lili Yang
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

Review 8.  Nutritional Approach to Cancer Cachexia: A Proposal for Dietitians.

Authors:  Kotone Tanaka; Sho Nakamura; Hiroto Narimatsu
Journal:  Nutrients       Date:  2022-01-14       Impact factor: 5.717

Review 9.  Understanding Cachexia in Head and Neck Cancer.

Authors:  Sivaramakrishnan Muthanandam; Jananni Muthu
Journal:  Asia Pac J Oncol Nurs       Date:  2021-08-27

10.  A Retrospective Cohort Study of Myosteatosis and Quality of Life in Head and Neck Cancer Patients.

Authors:  Amy L Shaver; Katia Noyes; Heather M Ochs-Balcom; Gregory Wilding; Andrew D Ray; Sung Jun Ma; Mark Farrugia; Anurag K Singh; Mary E Platek
Journal:  Cancers (Basel)       Date:  2021-08-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.